Shanghai Serum Bio-Technology's ROE and earnings retention a...
Shanghai Serum Bio-Technology's ROE and earnings retention are poor despite respectable earnings growth. High payout ratio and lower-than-average net income growth could risk the company's growth, especially in troubled times. The recent decision to pay dividends may be to impress shareholders.
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more